Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents

Simple item page
dc.contributor.authorSalazar, Juan C
dc.contributor.authorCahn, Pedro
dc.contributor.authorYogev, Ram
dc.contributor.authorNegra, Marinella Della
dc.contributor.authorCastelli-Gattinara, Guido
dc.contributor.authorFortuny, Claudia
dc.contributor.authorFlynn, Patrica M
dc.contributor.authorGiaquinto, Carlo
dc.contributor.authorRuan, Ping K
dc.contributor.authorSmith, M Elizabeth
dc.contributor.authorMikl, Jaromir
dc.contributor.authorJelaska, Ante
dc.contributor.authorfor the PACTG 1051/BI Study Team
dc.date.accessioned2024-05-23T23:49:09Z
dc.date.available2024-05-23T23:49:09Z
dc.date.issued2008-09-12
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractObjective: To evaluate the efficacy, safety and tolerability of ritonavir-boosted tipranavir (TPV/r) in HIV-1-infected pediatric patients. Design: Open-label randomized pediatric trial (1182.14/PACTG1051) comparing TPV/r at two doses including an optimized background regimen. Methods: HIV-1-infected patients (2–18 years) with plasma viral load 1500 copies/ml or more were randomized to TPV/r 290/115 or 375/150 mg/m2 twice-daily oral solution and optimized background regimen. Week 48 efficacy, safety and tolerability results were evaluated. Results: Children (n = 115; 97% treatment experienced) were randomized to low or high dose therapy. Eighty-eight remained on-treatment through 48 weeks. Baseline characteristics were similar between dose groups. At study entry, half of the HIV-1 isolates were resistant to all protease inhibitors. At 48 weeks, 39.7% low-dose and 45.6% high-dose TPV/r recipients had viral load less than 400 copies/ml and 34.5 and 35.1%, respectively, achieved viral load less than 50 copies/ml. Vomiting, cough and diarrhea were the most frequent adverse events. Grade 3 alanine aminotransferase elevations were observed in 6.3% of patients. No grade 4 alanine aminotransferase or grade 3/4 aspartate aminotransferase elevations were reported. Conclusions: TPV/r achieved a sustained virologic response, showed a good safety profile and was well tolerated at either dose. In pediatric patients with high baseline resistance profiles, high-dose TPV/r tended to demonstrate a better sustained response.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1097/qad.0b013e32830c481b
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1318
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesAIDS;2008 Sep 12;22(14):1789-98
dc.rightsopenAccesses_ES
dc.subjectHIV-1es_ES
dc.subjectChildes_ES
dc.subjectAdolescentes_ES
dc.subjectRitonavires_ES
dc.titleEfficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescentses_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1097QAD.0b013e32830c481b.pdf
Size:
226.84 KB
Format:
Adobe Portable Document Format
Description:
10.1097/QAD.0b013e32830c481b_eng
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos